References
- Albertini R.J., Castle K.L., Borcherding W.R. T-cell cloning to detect the mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood. Proceedings of the National Academy of Sciences, USA 1982; 70: 6617–6621
- Ammenheuser M.M., Ward J.B., Whorton E.B., Killian J.M., Legator M.S. Elevated frequencies of 6-thioguanine resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: a prospective study. Mutation Research 1988; 240: 509–520
- Dempsey J.L., Morley A.A. Measurement of in vivo mutant frequency in lymphocytes in the mouse. Environmental Mutagensis 1986; 8: 385–391
- Eldjarn L., Pihl A. On the mechanism of chemical protection against ionizing radiation. The interaction of cystcamine and cystamine with proteins. Progress in Radiobiology, J.S. Mitchel. Oliver & Boyd, London 1956; 249–257
- Grahn D., Ainsworth E.J., Williamson F.S., Fry R.J.M. A program to study fission-neutron-induced chronic injury in cells, tissues and animal populations, using the JANUS reactor of the Argonne National Laboratory. Radiobiological Applications of Neutron Irradiation. International Atomic Energy Agency, Vienna 1972; 211–228
- Grdina D.J., Nagy B., Hill C.K., Wells R.L., Peraino C. The radioprotector WR-1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis 1985; 6: 929–931
- Grdina D.J., Nagy B., Sigdestad C.P. Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Pharmacology and Therapeutics 1988; 39: 21–25
- Grdina D.J., Sigdestad C.P., Carnes B.A. Protection by WR-1065 and WR-151326 against fission-neutron-induced mutations at the HGPRT locus in V79 cells. Radiation Research 1989; 117: 500–510
- Hill C.K., Nagy B., Peraino C., Grdina D.J. 2-[(amino-propyl)-amino]ethanethiol (WR-1065) is anti-neoplastic and anti-mutagenic when given during 60Co γ-ray irradiation. Carcinogenesis 1986; 7: 665–668
- Holwitt E.A., Koda E., Swenberg C.E. Enhancement of topoisomerase I-mediated unwinding of supercoiled DNA by the radioprotector WR-33278. Radiation Research 1990; 124: 107–109
- Jones I.M., Burkhart-Schultz K., Carrano A.V. A method to quantify spontaneous and in vivo induced thioguanine-resistant mouse lymphocytes. Mutation Research 1985; 147: 97–105
- Kataoka Y. The radiosensitivity of T and B lymphocytes. Radiation Biology Research Communications 1976; 3: 19–34
- Ku H.H. Notes on the use of propagation of error formulas. Journal of Research of the National Bureau of Standards—C. Engineering and Instrumentation 1966; 70: 263–273
- Leonard A., Maisin J.R. Effect of 2-B-aminoethylisothiourea (AET) against genetic damage induced by X-irradiation of male mice. Radiation Research 1964; 23: 391–395
- Maisin J.R., Moutschen J. Chemical protection of the alimentary tract of whole-body X-irradiated mice. II. Chromosome breaks and mitotic activity. Experimental Cell Research 1960; 21: 347–352
- Maisin J.R., Mattelin G., Lambiet-Collier M. Chemical protection against the long-term effects of a single whole-body exposure of mice to ionizing radiation. I. Life shortening. Radiation Research 1977; 71: 119–131
- Maisin J.R., Gerber G.B., Lambiet-Collier M., Mattelin G. Chemical protection against long-term effects of whole-body exposure of mice to ionizing radiation. III. The effects of fractionated exposure to C57B1 mice. Radiation Research 1980; 82: 487–497
- Milas L., Hunter N., Stephaens L.C., Peters L.J. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Research 1984; 44: 5567–5569
- Morley A.A., Trainor K.J., Seshadri R.S., Ryall R.G. Measurement of in vivo mutations in human lymphocytes. Nature 1983; 302: 155–156
- Nagy B., Dale P.J., Grdina D.J. Protection against cis-diammine-dichloroplatinum(II) cytotoxicity and mutagenicity in V79 cells by free radical scavenger 2-[(aminopropyl)amino]ethanethiol. Cancer Research 1986; 46: 1132–1135
- Ngo F.Q.H., Han A., Utsumi H., Elkind M.M. Comparative radiobiology of fast neutrons: relevance to radiotherapy and basic studies. International Journal of Radiation Oncology, Biology and Physics 1977; 3: 187–193
- Niklas J.A., Falta M.T., Hunter T.C., O'Neill J.P., Jacobson-Kram D., Williams J.R., Albertini R.J. Molecular analysis of in vivo hprt mutations in human T lymphocytes. V. Effects of total body irradiation secondary to radioimmunoglobulin therapy (RIT). Mutagenesis 1990; 5: 461–468
- O'Neill J.P., McGinniss M.J., Berman J.K., Sullivan L.M., Nicklas J.A., Albertini R.J. Refinement of a T-lymphocyte cloning assay to quantify the in vivo thioguanine-resistant mutant frequency in humans. Mutagenesis 1987; 2: 87–94
- Sigdestad C.P., Grdina D.J., Connor A.M., Hanson W.R. A comparison of radioprotection from three neutron sources and 60Co by WR-2721 and WR-151327. Radiation Research 1986; 106: 224–233
- Smoluk G.D., Fahey R.C., Calabro-Jones P.M., Aguilera J.A., Ward J.F. Radioprotection of cells in culture by WR-2721 and derivatives: Form of the drug responsible for protection. Cancer Research 1988; 48: 3641–3647
- Trainor K.J., Wigmore D.J., Chrysostomou A., Dempsey J.L., Seshadri R., Morley A.A. Mutation frequency in human lymphocytes increases with age. Mechanisms of Aging and Development 1988; 27: 83–86
- Yuhas J.M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropyl-amino)ethylphosphorothioic acid. Cancer Research 1980; 40: 1519–1524